| ID | 1123 |
| Name of the vaccine | MENVEO |
| Microbe | Bacteria |
| Disease name | Meningococcal disease |
| Name of bacteria | Neisseria meningitidis |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | 2 months to 55 years |
| Description of the vaccine | Meningococcal (Groups A, C, Y, and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine. |
| Name of the manufacturer | GSK Vaccines |
| Name of the manufacturing country | Sovicille (SI), Italy |
| Year of manufacture | 2010 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative diplococcus. |
| Efficacy | NA |
| Vaccine formulation | Lyophilized MenA conjugate vaccine component reconstituted with MenCYW-135 liquid conjugate vaccine component. |
| Dosage | Primary Vaccination -
2 months children : 4-dose series at 2, 4, 6, and 12 months of age.
Children initiating vaccination at 7 months through 23 months : 2-dose series.
Individuals (2 year-55 years) : a single dose of 0.5 ml.
Booster - single booster dose individuals aged 15 to 55 years after 4 years.
|
| Mechanism of action | Production of bactericidal antibodies against the capsular polysaccharides of serogroups A, C, Y, and W-135. |
| Route of administration | Intramuscular |
| Indications | To prevent invasive meningococcal caused by Neisseria meningitidis serogroups A, C, Y and W-135. It does not prevent N meningitidis serogroup B disease. |
| Export | Distributed by - GlaxoSmithKline |
| Approval | US FDA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | For children- tenderness, injection site pain, erythema, irritability, sleepiness, persistent crying , change in eating habits, vomiting, diarrhoea, malaise and headache.
Adolescents and adults- injection site pain, headache, myalgia, malaise, nausea. |
| Post vaccination | NA |
| Dose type | Both |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/78514/download |
| Other name | NA |
| Additional Links | NA
|